Alzheimer's Research Is Shifting: Why Scientists Now Believe a Multi-Target Approach Is the Key
Decades of single-target treatments have fallen short. Scientists now argue Alzheimer's demands a whole-system strategy to truly make progress.
The Old Approach to Alzheimer's Isn't Working
For decades, researchers have pursued Alzheimer's disease by zeroing in on one biological culprit at a time. The results have been deeply disappointing. Even the newest wave of treatments — monoclonal antibodies like lecanemab and donanemab — offer only modest slowing of cognitive decline. They do not reverse the disease or restore lost brain function. Now, a growing number of scientists are calling for a fundamental rethink of how we approach one of the world's most devastating neurological conditions.
A comprehensive review published in Science China Life Sciences, led by Professor Yan-Jiang Wang and colleagues, makes a compelling case: Alzheimer's disease is not a single-cause problem, and treating it like one has been a critical mistake.
A Disease Far More Complex Than Previously Understood
Alzheimer's develops through the intersection of multiple biological, genetic, and systemic forces. These include the accumulation of amyloid-beta (Aβ) plaques, the formation of Tau protein tangles inside brain cells, inherited genetic risk factors, age-related cellular deterioration, and broader health conditions affecting the entire body.
No single drug can address all of these factors simultaneously — and that, researchers argue, is precisely why so many clinical trials have ended in failure.
The Role of Amyloid and Tau
Amyloid-beta has dominated Alzheimer's research for years, but therapies targeting it alone have produced limited outcomes. Scientists are now placing greater emphasis on Tau hyperphosphorylation — a damaging process that causes neurofibrillary tangles to form and brain cells to die off. The emerging consensus is that effectively slowing Alzheimer's will require treatments that address both Aβ accumulation and Tau pathology in tandem.
Genetics and the Promise of Gene Editing
Genetics remain a powerful driver of Alzheimer's risk. The APOE ε4 gene variant is the most well-known risk factor, but researchers are continuously identifying additional genetic contributors that vary across different population groups. Perhaps most exciting is the exploration of CRISPR/Cas9 gene-editing technology as a potential one-time therapeutic intervention — one that could modify a person's genetic risk profile at its very source before the disease takes hold.
How Aging and Overall Health Shape the Disease
Aging is the single greatest risk factor for Alzheimer's, and it brings with it a cascade of biological changes that make the brain increasingly vulnerable. These changes include declining mitochondrial efficiency, the accumulation of damaged and dysfunctional cells, and mounting DNA damage over time.
Researchers are now investigating "senolytic" therapies — treatments designed to selectively clear out aging glial cells that contribute to neuroinflammation and cognitive decline. By removing these malfunctioning cells, scientists hope to create a healthier brain environment that resists disease progression.
The Gut-Brain Connection
Alzheimer's does not exist in isolation within the brain. Systemic health conditions — including insulin resistance, high blood pressure, and disruptions in the gut microbiome — can actively worsen disease processes. This has opened the door to investigating whether existing diabetes medications and therapies targeting the gut-brain axis might offer meaningful protective or therapeutic benefits for Alzheimer's patients.
Moving Toward Integrated, Multi-Target Strategies
The core message from Wang and colleagues is a shift away from reductionist thinking and toward integrated, multi-pronged treatment strategies. Rather than attacking one aspect of the disease, future therapies should aim to address several interconnected mechanisms simultaneously.
This approach will also rely on more sophisticated research tools. Human iPSC-derived brain organoids — essentially miniature lab-grown brain models — offer researchers a far more accurate platform for testing new treatments than traditional methods. Meanwhile, precision medicine guided by early biomarkers such as plasma pTau217 could allow clinicians to detect Alzheimer's earlier and tailor interventions before significant damage occurs.
A More Hopeful Path Forward
"Success in defeating Alzheimer's hinges on interdisciplinary collaboration and holistic innovation," the authors conclude. Their review outlines a future in which Alzheimer's is no longer seen as an inevitable descent into cognitive loss, but rather as a complex, manageable — and potentially preventable — condition.
The science is evolving rapidly. What remains essential is the willingness to abandon outdated frameworks and embrace the full biological complexity of a disease that affects millions of families worldwide.
